AddLife Rebuilds the Deal Engine, Not Just the Deal Count
A 7% sales quarter is unremarkable; a decentralized acquisition machine handed to business-unit leaders is not — and it is the only truly novel thing on the tape today.
ALIF-B.ST · Earnings Call · 2026-10-21
The quarter itself is the boring part
AddLife's Q3 2026 (reported 21 October) reads like a competent continuation: sales up 7%, split almost evenly between 4% organic and 3% acquired, adjusted EBITA up 11% to an 11.5% margin, operating cash flow up 62% on working-capital release, leverage at 2.5x — comfortably under the 3x ambition, with bank facilities refinanced post-quarter for three years. Labtech's EBITA margin jumped to 12.9% from 11.2%; Medtech slipped to 11.3% from 11.6%. Nobody would build a story out of that alone.
The story is that management spent the call explaining the machinery behind the acquisitions it has been promising for several quarters, and admitted the organic line is not where the earnings leverage is coming from. “Organic growth of 4% reflects market growth.” — Christina Rubenhag, CFO · 2026-10-21 That is the CFO being unusually candid: this is participation, not share capture. Labtech organically grew just 2% against a 9% comparison. The incremental profit is coming from gross-margin mix and from bought-in businesses — a different kind of company than the "organic momentum" framing implies.
The deal machine finally gets a gearbox
Go back to July. Jakob Lembke put the awkward question plainly: “you have only added 2% to top line from M&A, which I guess is below your ambitions.” — Jakob Lembke, Analyst · 2026-07-16 Fredrik Dalborg did not dodge it — “We do need to increase the pace” — Fredrik Dalborg, CEO · 2026-07-16 — but the answer was aspiration, pipeline adjectives, and "we're on the right track." Three months later acquired growth is 3%, which is a step, not a transformation. Yet the top-ranked theme in this company's keyword trajectory is now acquisition activity, because what changed is not the arithmetic but the org chart.
I think we have gone from responsibility more centralized for the M&A to clear responsibility with the business unit leaders... they have the ability to find good targets. They have the ability to really assess the quality of the targets as well.
That is a real structural claim. Each business-unit leader now owns their own acquisition funnel; a group of senior advisers — former CEOs and unit heads — has been assembled to help identify and approach targets; two people now work purely on transactions; and lead generation is being staffed so that "the vast majority of the companies that we are in process with are indeed exclusive dialogues." Dalborg also reframed the pipeline as "4 or 5 different pipelines" rather than one, which is a resilience argument rather than a size argument.
This is the decentralized model extended from operations into capital allocation — an old slogan ("120 years," per the CEO) applied to a genuinely new function. And critically, it is company-unique. Scan the global top-75 for the quarter and you get Fed hiking cycles, mortgage universes, AI data-center spending and beer brands. AddLife is not riding any of those waves; it is trading on its own idiosyncratic thesis, which is exactly what makes it worth reading this week and not next.
Margins are carrying what volume isn't
The engine of the margin story is Advanced products: differentiated kit that lifts gross margin (up a full point this quarter) but demands clinical support staff ahead of the revenue. As the CFO put it, “sometimes you need to have the resources before you really have seen the sales.” — Christina Rubenhag, CFO · 2026-10-21 That is why the quarter carried "unusually high" operating expenses and why Medtech's margin dipped — summer elective-surgery lull plus pre-built support capacity.
The most useful number on the call was not in the release. Analysts pressed for a split between self-help and structural improvement; Christina Rubenhag instead returned to the CMD matrix of two years ago, where roughly 25% of revenue sat in the low-margin, low-return corner — “by end of '25, it was around 20%” — Christina Rubenhag, CFO · 2026-10-21, still shrinking. That is a slow, unglamorous, high-confidence value lever that does not show up in a 4% organic print.
There is also a recurring tell worth flagging. For the second quarter running, an analyst asked whether Labtech's margin was one-off-inflated. For the second quarter running the answer was a flat denial — “Nothing of the kind of onetime impact type really” — Fredrik Dalborg, CEO · 2026-10-21 versus July's “Nothing particular in terms of one-offs really.” — Fredrik Dalborg, CEO · 2026-07-16 The answer's shape hasn't changed, but its supporting evidence has: tender wins that take one to two years to install, complete portfolio takeovers including the teams, and acquisitions contributing roughly a 30% EBITA margin. The durability argument got better even as the sentence stayed the same.
What management quietly stopped talking about
The most interesting signal is an absence. In Q2 the company's top themes were Home Care — the single highest-ranked keyword — and Eye surgery, both turnaround stories management wanted credit for. Neither appears as a theme this quarter; eye surgery has vanished from the trajectory entirely, and Home Care resurfaces only as LEHNEN, the German stainless-steel manufacturer acquired in October. When a fix stops being a talking point, it is usually because it is no longer a problem.
The U.K. is the clearest resolution. In July, analysts circled capital-equipment conversion and book-to-bill; Dalborg offered only “gradual improvements and not a dramatic shift” — Fredrik Dalborg, CEO · 2026-07-16. On Wednesday the deliveries actually landed, order books were called healthy and "normalized," and management described good growth in the U.K. and Ireland with a positive trend in surgical procedures performed. Waiting lists remain long — which is the forward demand argument — but the multi-quarter deferral debate appears closed.
Spain is the mirror image, and the dissonance is the point. Strikes in Spain was a top-15 theme last quarter. It is not a theme now, yet the CEO was blunter than ever: “I think we will probably see more strikes in the coming months, I'm afraid” — Fredrik Dalborg, CEO · 2026-10-21, adding that the underlying dispute "is not solved." The drag persists; the narrative has simply moved past it. That cuts both ways — the deferred procedures are a stored asset, but a market that has stopped discounting Spanish risk may be under-pricing a slower Q4.
The read
AddLife is asking investors to underwrite three things: acquired growth climbing from 3% toward double digits now that deal sourcing sits with the people closest to the market; a problem-child bucket that keeps walking itself out of the bottom-left corner; and organic growth that holds at market while mix does the margin work. Leverage at 2.5x gives room for all three. What there is no confirmation of is price — no share-price tape is available for this name, and there is no press coverage in the window, so this is a thesis built entirely from what management said and did not say. The genuinely new item is the M&A organization. Everything else, including the reassuring tone, is continuity — and continuity, at this company, has historically been worth roughly market growth.